Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.
Mironid has raised $45.9M in total funding. The most recent round was Series B. The last funding was announced in August 2026.
Mironid's investors include Epidarex Capital, Sofinnova Partners, University of Strathclyde, BioGeneration Ventures, European Investment Fund.
Mironid is headquartered in Newhouse, United Kingdom.
Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.
Mironid is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mironid — Funding & Investors." VCBacked, August 5, 2026, https://www.vcbacked.co/company/mironid. Accessed October 30, 2026.
VCBacked. (2026). Mironid — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/mironid
{{cite web |title=Mironid — Funding & Investors |url=https://www.vcbacked.co/company/mironid |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated